Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01514669 · ClinicalTrials.gov registry record
Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer
A clinical trial of Prostate Cancer, sponsored by University of Arkansas.
- Active
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT01514669 is a study of Prostate Cancer that is active but no longer recruiting, run by University of Arkansas. The registered enrollment target is 75 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01514669, a study of Prostate Cancer, is active but no longer recruiting, sponsored by University of Arkansas.
- ACTIVE NOT RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to compare profiles in the blood and tears of patients with and without prostate cancer with the goal of developing a method of separating men with aggressive and non-aggressive disease.
Conditions Studied
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2012-01-01 |
| Est. Completion | 2027-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01514669
The ClinicalTrials.gov registry entry for NCT01514669 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01514669 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT01514669 about?
NCT01514669 is a clinical study titled "Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer". The purpose of this research study is to compare profiles in the blood and tears of patients with and without prostate cancer with the goal of developing a method of separating men with aggressive and non-aggressive disease.
What is the current status of trial NCT01514669?
This trial is currently active not recruiting. The enrollment target is 75 participants. The study started on 2012-01-01. Estimated completion is 2027-02.
What conditions does trial NCT01514669 study?
This clinical trial studies the following conditions: Prostate Cancer.
Who is sponsoring clinical trial NCT01514669?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01514669 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.